NHS England has begun rolling out a subcutaneous injectable form of pembrolizumab, known commercially as Keytruda and marketed in the United States as Keytruda Qlex, manufactured by Merck Sharp and Dohme, the European trading name of Merck and Company (NYSE: MRK). The new formulation reduces administration time from a 30-minute to 2-hour intravenous infusion to a 1-minute subcutaneous injection every three weeks, or a 2-minute injection every six weeks, depending on cancer type. Around 14,000 patients begin pembrolizumab therapy each year in England, and the bulk of that patient population is now expected to transition to the injectable version. For Merck and Company, which generated $31.7 billion in Keytruda revenue in 2025 and reported $8.0 billion in Keytruda sales in the first quarter of 2026, the NHS rollout is far more than a patient-convenience story. It is one of the most operationally important defensive moves of the entire 2025 to 2028 patent cliff cycle in big pharma.
Why is the NHS rollout of subcutaneous Keytruda a strategic event for Merck and Company rather than a routine drug delivery upgrade?
The headline framing across UK media has focused almost entirely on patient experience and NHS productivity. That framing understates what is actually happening. Merck and Company is running one of the largest defensive lifecycle extensions in pharmaceutical history. Keytruda’s primary United States composition-of-matter patent expires in late 2028, with method-of-use and manufacturing patent extensions that Merck and Company expects to defend into 2029. Beyond that point, biosimilar manufacturers including Samsung Bioepis, Amgen, Celltrion, Formycon partnered with Zydus, and several Indian biosimilar developers are positioned to enter the market with substantial price erosion in both the European Union and the United States.
The subcutaneous formulation, branded Keytruda Qlex in the United States and marketed as Keytruda SC in several international markets, was approved by the United States Food and Drug Administration in September 2025. Its patent protection extends beyond 2030, materially longer than the intravenous formulation. Every patient that Merck and Company can convert from the intravenous version to the subcutaneous version before the 2028 loss of exclusivity is, in effect, a patient that biosimilar competitors will struggle to reach. Management has publicly targeted 30 to 40 percent conversion of the existing Keytruda patient base to Keytruda Qlex by 2028. The NHS, which treats roughly 14,000 new pembrolizumab starts each year, is a strategically important conversion pool because of its scale, its centralised procurement, and the speed with which national health systems can shift practice once a formulation is approved.
The NHS rollout is therefore best understood as the British leg of a global conversion programme that Merck and Company is running against a non-negotiable clock.
How does the 60-second injection actually change the economics of cancer care for the NHS and for Merck and Company?
For NHS England, the operational case is straightforward. Hospital pharmacy teams currently prepare intravenous bags of pembrolizumab under specialist sterile conditions, a process that consumes pharmacist time, requires controlled environments, and adds to the total chair time per patient. The ready-to-administer subcutaneous injection eliminates that preparation step entirely. Patients spend less time in chemotherapy chairs, clinic capacity expands without new infrastructure, and oncology day units gain throughput at a moment when waiting times remain a politically charged metric for the United Kingdom government. Health and Social Care Secretary Wes Streeting framed the rollout in exactly those terms, citing waiting time reduction, treatment-on-time targets, and early diagnosis improvement.
For Merck and Company, the economics work in two directions. Subcutaneous formulations of established biologics typically command pricing parity with their intravenous counterparts in the early years, even though manufacturing costs are higher. More importantly, the conversion buys time. A patient on Keytruda Qlex in 2027 is unlikely to be switched back to an intravenous biosimilar in 2029 unless the price gap is severe and the clinical case is compelling, because clinicians and patients both prefer the shorter administration time. This is the same playbook that biologics manufacturers have used to defend franchises in inflammatory disease and oncology when faced with biosimilar entry. The difference is scale. Keytruda is the highest-grossing pharmaceutical product in the world, and the conversion window is narrow.
The phase 3 3475A-D77 trial, which compared subcutaneous and intravenous pembrolizumab in combination with chemotherapy for metastatic non-small-cell lung cancer, demonstrated comparable pharmacokinetic profiles, comparable clinical efficacy, and a consistent safety record. That clinical equivalence is what allows the conversion narrative to work. Without it, oncologists would resist the switch, and the entire defensive strategy would lose its foundation.
What does the NHS rollout signal about Merck and Company’s broader patent cliff defence and pipeline transition?
Merck and Company is executing what management has described as a transformation from a single-asset narrative to a diversified pipeline-driven business. Chief Executive Officer Robert Davis has publicly framed the company’s commercial opportunity through the mid-2030s at roughly $70 billion across more than 20 growth drivers. Winrevair, the pulmonary arterial hypertension therapy launched in 2024, generated $525 million in the first quarter of 2026, an 88 percent year-on-year increase, and is on a trajectory that several sell-side analysts now model toward $5 billion to $7 billion in peak sales. The 2025 Verona Pharma acquisition for approximately $10 billion brought Ohtuvayre into the cardiopulmonary franchise. The Cidara Therapeutics acquisition in early 2026, which contributed a $9 billion upfront charge to Q1 2026 results and produced a headline GAAP loss, added a long-acting antifungal asset.
Within that broader transformation, Keytruda Qlex is not optional infrastructure. It is the bridge that funds everything else. As long as Merck and Company can keep the Keytruda franchise generating $25 billion to $30 billion in annual revenue through 2030, the cash flow underwrites the pipeline transition, the dividend, the buybacks, and the continued bolt-on acquisitions. If Keytruda revenue collapses faster than modelled, the entire transition becomes harder to finance without balance-sheet stress.
The NHS rollout is one of the earliest, most operationally visible examples of the conversion strategy being executed at national-system scale. Northern Ireland began an injectable Keytruda transition across three of its five health trusts in April 2025 under Health Minister Mike Nesbitt, and the England and Wales rollout from May 2026 is the next phase. Other European national health systems are expected to follow given the operational case. The pace of conversion through the rest of 2026 and 2027 will be one of the most important leading indicators of how successfully Merck and Company can flatten the post-2028 revenue cliff.
How are markets pricing Merck and Company shares against the patent cliff narrative?
Merck and Company shares have traded in a band roughly between $111 and $120 through the first half of 2026, with a market capitalisation in the $286 billion range. The stock delivered a total return of approximately 24.9 percent in the 12 months to March 2026, outperforming the broader pharmaceutical sector as investors rotated toward companies with strong cash flows and visible dividends. First quarter 2026 revenue came in at $16.29 billion, up 4.87 percent year-on-year and ahead of consensus, with Keytruda revenue of $8.03 billion beating estimates of $7.7 billion. The Cidara Therapeutics acquisition charge produced a headline GAAP loss for the quarter, but Merck and Company narrowed its full-year revenue guidance to $65.8 billion to $67 billion and raised adjusted earnings per share guidance to $5.04 to $5.16.
Wall Street consensus on Merck and Company sits at roughly 62 percent bullish, with no sell ratings on the most recent count. Scotiabank raised its price target to $136 from $120 after fourth quarter 2025 results. A bull-case scenario from one widely-circulated sell-side model lands at $141.16, implying total return of around 29 percent. The bear case centres squarely on the Keytruda patent cliff, the China collapse in Gardasil revenue, and three failed Phase 3 oncology trials including LITESPARK-012, KEYNOTE-975, and KEYNOTE-866. The bear case still lands at $114.09, modest upside that reflects the floor provided by the dividend and free cash flow generation.
The market is, in short, already pricing in a degree of patent cliff erosion. What it is not yet fully pricing in is the upside scenario in which Keytruda Qlex conversion reaches the upper end of management’s 30 to 40 percent target before 2028, biosimilar erosion comes in slower than the historical 70 to 80 percent loss within two to three years of loss of exclusivity, and the cardiopulmonary franchise reaches multi-billion-dollar scale on schedule. Each NHS-style rollout is an incremental data point that bulls can use to argue that Merck and Company’s lifecycle defence is working better than the consensus model assumes.
What are the second-order industry implications for biosimilar developers and competing checkpoint inhibitor manufacturers?
The biosimilar wave targeting Keytruda is one of the largest commercial opportunities in biosimilar history. Samsung Bioepis, Amgen, Celltrion, and Formycon partnered with Zydus are among the developers most advanced in their programmes. Indian biosimilar manufacturers, including several with active preclinical and clinical work, are positioning for both their domestic market and the broader emerging market opportunity. Each of these developers has built financial models that assume a relatively rapid conversion of intravenous Keytruda demand to biosimilar pembrolizumab once the loss of exclusivity arrives.
The subcutaneous rollout changes those models. If 30 to 40 percent of Merck and Company’s pembrolizumab patient base is on Keytruda Qlex by the time biosimilars enter, the addressable intravenous market for biosimilars shrinks proportionally. Biosimilar developers will need to either pursue their own subcutaneous formulations, which carries its own development cost and timeline, or accept a smaller commercial opportunity than initial models suggested. Some developers have already begun exploring subcutaneous biosimilar pembrolizumab pathways, but the regulatory and clinical bar for subcutaneous biosimilars is higher than for straightforward intravenous biosimilars, and Merck and Company’s berahyaluronidase alfa-pmph co-formulation is itself patent-protected.
For competing checkpoint inhibitor manufacturers, the message is different. Bristol-Myers Squibb’s Opdivo, manufactured under the Bristol-Myers Squibb brand, has its own subcutaneous formulation called Opdivo Qvantig, approved in late 2024. Roche’s Tecentriq subcutaneous version received approval in 2024. The competitive battleground in PD-1 and PD-L1 immunotherapy has effectively shifted from molecule efficacy, where the major agents are broadly comparable in most settings, to administration convenience, combination strategy, and lifecycle defence. The NHS rollout positions Keytruda Qlex on the leading edge of that shift in the United Kingdom market.
What execution risks could undermine Merck and Company’s Keytruda Qlex conversion strategy?
The conversion strategy carries three significant execution risks that institutional investors should track through 2026 and 2027.
The first is reimbursement complexity. The NHS rollout is operationally clean because the National Institute for Health and Care Excellence approved subcutaneous pembrolizumab and the system is centralised. In other markets, including the United States, payer-by-payer formulary placement, prior authorisation processes, and site-of-care reimbursement differences could slow conversion. Hospital outpatient departments earn revenue on infusion administration, and a shift to subcutaneous injection that can be administered in a clinic setting changes the economics for some providers. Merck and Company will need to manage that transition carefully across thousands of payer and provider relationships.
The second is the patent litigation pathway. Merck and Company has indicated growing confidence in defending method-of-use and manufacturing patents that extend Keytruda intellectual property into 2029. Biosimilar developers are likely to challenge those extensions vigorously. The outcome of that litigation will determine whether the cliff begins in late 2028 or shifts incrementally into 2029, and whether the conversion strategy has 24 months of runway or 36 months.
The third is the broader pipeline execution risk. Three failed Phase 3 oncology trials in the past 18 months, including LITESPARK-012, KEYNOTE-975, and KEYNOTE-866, have already reduced confidence in the diversification narrative. The June 2026 Oncology Investor Event at the American Society of Clinical Oncology meeting and the June 19, 2026 PDUFA date for Welireg in combination with Keytruda for adjuvant renal cell carcinoma are both near-term catalysts that will materially shape the pipeline narrative. Strong outcomes accelerate the bull case. Weak outcomes will force investors to lean even more heavily on Keytruda Qlex conversion as the primary patent cliff defence.
Key takeaways on what the NHS rollout of subcutaneous Keytruda means for Merck and Company, its competitors, and the immunotherapy industry
- The NHS rollout of subcutaneous pembrolizumab is best understood as the British leg of a global lifecycle defence strategy by Merck and Company, not as a standalone patient-convenience story
- Keytruda Qlex carries patent protection into the 2030s, materially longer than the 2028 loss of exclusivity facing intravenous Keytruda, making every patient conversion a defensive lock-in against biosimilar entry
- Management has publicly targeted 30 to 40 percent patient conversion to subcutaneous Keytruda by 2028, and centralised national health systems like the NHS are the highest-leverage conversion pools
- Around 14,000 NHS patients begin pembrolizumab therapy each year in England, with most expected to transition to the subcutaneous formulation, providing a near-term operational test of the conversion strategy at scale
- First quarter 2026 Keytruda revenue of $8.03 billion, up 12 percent year-on-year, demonstrates that the underlying franchise is still expanding even as the cliff approaches
- The biosimilar opportunity for Samsung Bioepis, Amgen, Celltrion, and Formycon partnered with Zydus shrinks proportionally with every successful Keytruda Qlex conversion before 2028
- Competing checkpoint inhibitor manufacturers including Bristol-Myers Squibb with Opdivo Qvantig and Roche with subcutaneous Tecentriq have already shifted the immunotherapy battleground from molecule efficacy to administration convenience and lifecycle defence
- Merck and Company shares have traded in the $111 to $120 band through 2026, with bull-case sell-side targets at $141 and consensus around $118, reflecting a market that is partially but not fully pricing in successful patent cliff defence
- The Cidara Therapeutics acquisition charge of $9 billion in Q1 2026 produced a headline GAAP loss but reflects continued bolt-on diversification underwritten by Keytruda cash flow
- The pace of national health system rollouts of subcutaneous Keytruda through 2026 and 2027 will be one of the most important leading indicators of how successfully Merck and Company can flatten the post-2028 revenue cliff into a manageable hill
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
